Event of special interest | PF-06410293 n = 297 n (%) | Adalimumab-EU n = 299 n (%) | Risk difference (95% CI) (%) |
---|---|---|---|
Injection-site reactions | 5 (1.7) | 6 (2.0) | −0.32 (−2.84, 2.12) |
Opportunistic infections | 7 (2.4) | 5 (1.7) | 0.69 (−1.80, 3.32) |
Herpes zoster | 1 (0.3) | 3 (1.0) | −0.67 (−2.61, 0.97) |
Latent tuberculosis | 5 (1.7) | 1 (0.3) | 1.35 (−0.35, 3.59) |
Confirmed active tuberculosis | 0 | 0 | 0 (NA) |
Oral candidiasis | 0 | 1 (0.3) | −0.33 (−1.87, 0.95) |
Pneumocystis jirovecii pneumonia | 1 (0.3) | 0 | 0.34 (−0.94, 1.88) |
Urticaria, angioedema, anaphylactic reactiona | 0 | 2 (0.7) | −0.67 (−2.41, 0.61) |